Why is Yusimry so Hard to Find? [Explained for 2026]

If your doctor prescribed Yusimry (adalimumab-aqvh) and your pharmacy can't fill it, you're not imagining things. Many patients across the country run into the same wall — and it has nothing to do with a manufacturing problem. Yusimry is being made and is available. The challenge is a complex web of insurance rules, pharmacy stocking decisions, and market dynamics that can make a perfectly available drug feel impossible to find.

Here's what's really going on — and, more importantly, what you can do about it.

Is Yusimry in an Official FDA Shortage?

No. As of 2026, Yusimry is not listed on the FDA's drug shortage database, and it is not on the ASHP shortage list. Coherus BioSciences (and its distribution partner Meitheal Pharmaceuticals) are actively manufacturing and distributing Yusimry. The supply chain is intact.

So if it's not a shortage, why are patients having trouble filling their prescriptions? The answer lies in how the adalimumab biosimilar market works — and how pharmacy benefit managers (PBMs) control what ends up on pharmacy shelves.

What Is Yusimry, and Why Are There So Many Biosimilars?

Yusimry is a biosimilar to Humira (adalimumab), one of the best-selling drugs in history. When Humira's patents expired, multiple pharmaceutical companies received FDA approval to make biosimilar versions — highly similar copies with no clinically meaningful differences in safety or efficacy. Yusimry was approved by the FDA on December 17, 2021 and launched in July 2023.

Over 10 adalimumab biosimilars are now approved in the United States. That's a lot of competition — which is great for driving prices down, but creates a fragmented market where pharmacies can only stock a few at a time.

The Real Reason Yusimry Is Hard to Find: PBM Market Dynamics

The three largest pharmacy benefit managers — CVS Caremark, Express Scripts, and OptumRx — control about 80% of prescriptions dispensed in the United States. In 2024, each of these PBMs struck deals to promote "private-label" versions of adalimumab biosimilars on their formularies:

CVS Caremark prefers Cordavis private-label Hyrimoz (and unbranded Humira)

Express Scripts prefers Cyltezo and Simlandi (via Quallent Pharmaceuticals)

OptumRx prefers Amjevita (via its Nuvaila division)

Yusimry does not have a private-label arrangement with any of the three major PBMs. As a result, it holds only a small share of the total adalimumab market — around 3% in 2024 data. Pharmacies stock what their biggest payer contracts demand. If your pharmacy's top insurance contracts all push different biosimilars, Yusimry simply won't be on their shelves.

Why Your Insurance Might Not Cover Yusimry

Insurance formularies determine which drugs are covered and at what cost. Most commercial plans in 2026 prefer one or two specific adalimumab biosimilars based on their PBM's contracted rates. If Yusimry isn't on your plan's preferred list, you may face:

A denial or non-preferred tier placement requiring prior authorization

Step therapy requirements (trying another biosimilar first)

Higher out-of-pocket cost even if technically covered

This is one of the top reasons patients can't easily access Yusimry — even though it's legally available and clinically equivalent to other options on the formulary.

Specialty Pharmacy vs. Retail Pharmacy: Where Yusimry Is (and Isn't) Stocked

Most retail pharmacies — the CVS, Walgreens, or Rite Aid near your house — stock only one or two adalimumab biosimilars based on their most common insurance contracts. Yusimry is less likely to be stocked at retail chains unless their top payer prefers it.

However, Yusimry is available through certain specialty pharmacies and importantly through Mark Cuban's Cost Plus Drugs at $569.27 plus dispensing and shipping fees — significantly lower than its $995 list price per carton. This is actually one of the most accessible routes for patients without ideal insurance coverage.

Yusimry's Price Advantage — But Availability Challenges

Yusimry launched in July 2023 with a list price of $995 per carton (2 autoinjectors), representing approximately an 85% discount compared to Humira's list price of about $6,922 per carton. In employer claims data from 2024, Yusimry averaged just $639 per prescription — the lowest among adalimumab biosimilars analyzed.

Despite being the most affordable adalimumab biosimilar, Yusimry lacks the PBM partnerships that drive pharmacy stocking. Lower price doesn't automatically mean easier to find at your local pharmacy.

What Can You Do If You Can't Find Yusimry?

Here are concrete steps to take if your pharmacy doesn't have Yusimry:

Use medfinder.com — medfinder calls pharmacies near you to check which ones can fill your Yusimry prescription, saving you hours of phone calls.

Check Cost Plus Drugs — Yusimry is available at $569.27 (plus fees) through costplusdrugs.com. Ask your doctor to send your prescription there.

Call your insurance company — ask which adalimumab biosimilars are preferred on your formulary and whether you need prior authorization.

Ask your doctor about the Yusimry Solutions Copay Card — commercially insured patients can reduce their cost to as little as $0 per prescription. Call 1-800-987-4679.

Ask about switching biosimilars — if Yusimry remains unavailable, your doctor can prescribe another adalimumab biosimilar. Clinical studies show switching between adalimumab products is safe with no loss of efficacy.

The Bottom Line

Yusimry's availability problem is a market problem, not a manufacturing problem. The drug exists — it's just not being stocked at most pharmacies because of PBM formulary dynamics. The good news is that solutions exist: specialty pharmacies, Cost Plus Drugs, and tools like medfinder can all help you get your medication. If you can't get Yusimry, you may also want to read our guide to alternatives to Yusimry for other options your doctor may consider.

Don't spend hours calling pharmacies yourself. Let medfinder do the work for you — we'll find out which pharmacies near you have Yusimry in stock.